title: Tumor-specific gene therapy for undifferentiated thyroid carcinoma utilizing the telomerase reverse transcriptase promoter.
abstract: A tumor-specific targeting system for cancer gene therapy was studied using the human telomerase reverse transcriptase (hTERT) promoter. Telomerase activity is increased in most tumors but not detected in most normal cells. We developed the recombinant adenovirus, carrying human herpes simplex virus thymidine kinase gene under the control of the hTERT promoter (AdhTERTtk) to obtain restricted expression of a suicide gene only in tumor cells. We found that transcriptional activity of hTERT was 2- to 9-fold higher in undifferentiated thyroid carcinoma cell lines than that of the Simian virus 40 promoter in transient transfection assay. Undifferentiated thyroid carcinoma cell lines were infected with AdhTERTtk, and sensitivity to ganciclovir (GCV) was analyzed. Cell viability was decreased in a GCV dose-dependent manner after treatment with AdhTERTtk/GCV. The cell-killing ability of AdhTERTtk in all thyroid or nonthyroid carcinoma cell lines tested was similar to AdCMVtk, which carries herpes simplex virus thymidine kinase gene driven by the cytomegalovirus promoter. However, normal cell lines were largely unaffected by AdhTERTtk/GCV, whereas these cells were also sensitive to GCV after infection with AdCMVtk. A xenograft model was established by transplanting human differentiated or undifferentiated thyroid carcinoma cells into Balb-C nude mice. The injections of AdhTERTtk into tumors and ip administration of GCV showed significant inhibition of tumor growth, similar to AdCMVtk/GCV treatment. Systemic administrations of adenovirus and GCV to normal rats demonstrated remarkable increase of serum liver transaminase levels and severe hepatic damages in pathological examinations in AdCMVtk-injected rats but not in the AdhTERTtk group. These results indicate that the AdhTERTtk/GCV system is a promising therapy for undifferentiated thyroid carcinoma, which is one of the most malignant tumors, without damage to normal tissues.
authors.affiliation: Department of Aging Medicine and Geriatrics, Shinshu University, Graduate School, Matsumoto, Nagano 390-8621, Japan. teiji@hsp.md.shinshu-u.ac.jp
authors.forename: Teiji
authors.initials: T
authors.lastname: Takeda
authors.forename: Hidehumi
authors.initials: H
authors.lastname: Inaba
authors.forename: Masanori
authors.initials: M
authors.lastname: Yamazaki
authors.forename: Satoru
authors.initials: S
authors.lastname: Kyo
authors.forename: Takahide
authors.initials: T
authors.lastname: Miyamoto
authors.forename: Satoru
authors.initials: S
authors.lastname: Suzuki
authors.forename: Takashi
authors.initials: T
authors.lastname: Ehara
authors.forename: Tomoko
authors.initials: T
authors.lastname: Kakizawa
authors.forename: Masahiro
authors.initials: M
authors.lastname: Hara
authors.forename: Leslie J
authors.initials: LJ
authors.lastname: DeGroot
authors.forename: Kiyoshi
authors.initials: K
authors.lastname: Hashizume
mesh_terms: D000256:Adenoviridae / Q000235:genetics; D000818:Animals; D002277:Carcinoma / Q000235:genetics / Q000628:therapy*; D002470:Cell Survival; D004268:DNA-Binding Proteins; D015316:Genetic Therapy; D006801:Humans; D008297:Male; D010957:Plasmids / Q000235:genetics; D011401:Promoter Regions, Genetic / Q000235:genetics*; D051381:Rats; D019098:Telomerase / Q000235:genetics*; D013964:Thyroid Neoplasms / Q000235:genetics / Q000628:therapy*; D014162:Transfection; D014407:Tumor Cells, Cultured
chemical_list: D004268:DNA-Binding Proteins; D019098:Telomerase